Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-ws8qp Total loading time: 0 Render date: 2024-03-28T19:28:22.275Z Has data issue: false hasContentIssue false

18 - Drug Augmentation Strategies for Treatment-Resistant Obsessive-Compulsive and Related Disorders

from Section 2 - Practical Aspects of Obsessive-Compulsive Disorder

Published online by Cambridge University Press:  14 December 2018

Leonardo F. Fontenelle
Affiliation:
Federal University of Rio de Janeiro
Murat Yücel
Affiliation:
Monash University, Victoria
Get access
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bandelow, B, Zohar, J, Hollander, E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry. 2008;9(4):248312.CrossRefGoogle ScholarPubMed
Hollander, E, Allen, A, Kwon, J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56(11):10331039.CrossRefGoogle ScholarPubMed
Johnson, J, El-Alfy, AT. Review of available studies of the neurobiology and pharmacotherapeutic management of trichotillomania. J Adv Res. 2016;7(2):169184.CrossRefGoogle ScholarPubMed
Brakoulias, V, Eslick, GD, Starcevic, V. A meta-analysis of the response of pathological hoarding to pharmacotherapy. Psychiatry Res. 2015;229(1–2):272276.Google Scholar
Mataix-Cols, D, Fernández de la Cruz, L, Nordsletten, AE, Lenhard, F, Isomura, K, Simpson, HB. Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. World Psychiatry. 2016;15(1):8081.Google Scholar
Belotto-Silva, C, Diniz, JB, Malavazzi, DM, et al. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. J Anxiety Disord. 2012;26(1):2531.Google Scholar
Diniz, JB, Shavitt, RG, Fossaluza, V, Koran, L, de Braganca Pereira, CA, Miguel, EC. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol. 2011;31(6):763768.CrossRefGoogle ScholarPubMed
Jakubovski, E, Diniz, JB, Valério, C, et al. Clinical predictors of long-term outcome in obsessive-compulsive disorder. Depress Anxiety. 2013;30(8):763772.Google Scholar
Costa, DL, Diniz, JB, Miguel, EC. How similar are the disorders included under the umbrella of obsessive-compulsive disorder and related disorders? JAMA Psychiatry. 2016;73(8):877.Google Scholar
Foa, EB, Simpson, HB, Liebowitz, MR, et al. Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder. J Clin Psychiatry. 2013;74(5):464469.CrossRefGoogle ScholarPubMed
Simpson, HB, Foa, EB, Liebowitz, MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013; 70(11):11901199.Google Scholar
Keuthen, NJ, Tung, ES, Reese, HE, Raikes, J, Lee, L, Mansueto, CS. Getting the word out: cognitive-behavioral therapy for trichotillomania (hair-pulling disorder) and excoriation (skin-picking) disorder. Ann Clin Psychiatry. 2015;27(1):1015.Google Scholar
Williams, M, Viscusi, JA. Hoarding disorder and a systematic review of treatment with cognitive behavioral therapy. Cogn Behav Ther. 2016;45(2):93110.Google Scholar
Pampaloni, I, Sivakumaran, T, Hawley, C, et al. High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey. J Psychopharmacol. 2010; 24(10):14391445.Google Scholar
Math, S, Janardhan, Reddy Y. Issues in the pharmacological treatment of obsessive-compulsive disorder. Int J Clin Pract. 2007;61(7):11881197.Google Scholar
Simeon, J, Thatte, S, Wiggins, D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull. 1990;26(3):285290.Google Scholar
Browne, M, Horn, E, Jones, T. The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder. Can J Psychiatry. 1993;38(4):242243.Google Scholar
Diniz, JB, Shavitt, RG, Pereira, CAB, et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J Psychopharmacol. 2010;24(3):297307.Google Scholar
Ravizza, L, Barzega, G, Bellino, S, Bogetto, F, Maina, G. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull. 1996;32(1):167173.Google ScholarPubMed
Pallanti, S, Quercioli, L, Paiva, R, Koran, L. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry. 1999;14(2):101106.Google Scholar
Marazziti, D, Golia, F, Consoli, G, et al. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr. 2008;13(11):971976.Google Scholar
Andrade, C. Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: benefits and risks. J Clin Psychiatry. 2013;74(12):e1128e1133.Google Scholar
Diniz, JB, Costa, DL, Cassab, RC, Pereira, CA, Miguel, EC, Shavitt, RG. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder. J Psychopharmacol. 2013;28(6):603611.Google Scholar
Trivedi, MH, Fava, M, Wisniewski, SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):12431252.Google Scholar
Alevizos, B, Lykouras, L, Zervas, I, Christodoulou, G. Risperidone-induced obsessive-compulsive symptoms: a series of six cases. J Clin Psychopharmacol. 2002;22(5):461467.Google Scholar
Alevizos, B, Papageorgiou, C, Christodoulou, G. Obsessive-compulsive symptoms with olanzapine. Int J Neuropsychopharmacol. 2004;7(3):375377.Google Scholar
Ercan, ES, Ardic, UA, Ercan, E, Yuce, D, Durak, S. A promising preliminary study of aripiprazole for treatment-resistant childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2015;25(7):580584.Google Scholar
Bloch, M, Landeros-Weisenberger, A, Kelmendi, B, Coric, V, Bracken, M, Leckman, J. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622632.Google Scholar
Albert, U, Carmassi, C, Cosci, F, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol. 2016;31(5):249258.Google Scholar
Kim, C, Koo, M, Cheon, K, Ryu, Y, Lee, J, Lee, H. Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder. Eur J Nucl Med Mol Imaging. 2003;30(12):16371643.Google Scholar
van der Wee, N, Stevens, H, Hardeman, J, et al. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry. 2004;161(12):22012206.Google Scholar
Cheon, KA, Ryu, YH, Namkoong, K, Kim, CH, Kim, JJ, Lee, JD. Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naïve children with Tourette’s disorder. Psychiatry Res. 2004;130(1):8595.Google Scholar
Winogrodzka, A, Bergmans, P, Booij, J, van Royen, EA, Stoof, JC, Wolters, EC. [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74(3):294298.Google Scholar
Dell’Osso, B, Altamura, AC, Allen, A, Marazziti, D, Hollander, E. Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci. 2006;256(8):464475.Google Scholar
Denys, D, Klompmakers, A, Westenberg, H. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl). 2004;176(2):195203.Google Scholar
Zhang, W, Perry, K, Wong, D, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000;23(3):250262.Google Scholar
McDougle, C, Goodman, W, Leckman, J, Lee, N, Heninger, G, Price, L. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51(4):302308.Google Scholar
McDougle, C, Goodman, W, Price, L, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1990;147(5):652654.Google Scholar
Srour, M, Lespérance, P, Richer, F, Chouinard, S. Psychopharmacology of tic disorders. J Can Acad Child Adolesc Psychiatry. 2008;17(3):150159.Google Scholar
Van Ameringen, M, Mancini, C, Oakman, JM, Farvolden, P. The potential role of haloperidol in the treatment of trichotillomania. J Affect Disord. 1999;56(2–3):219226.Google Scholar
Dold, M, Aigner, M, Lanzenberger, R, Kasper, S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2015;18(9) pii: pyv047.Google Scholar
Van Ameringen, M, Mancini, C, Patterson, B, Bennett, M, Oakman, J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2010;71(10):13361343.CrossRefGoogle ScholarPubMed
Rothbart, R, Stein, DJ. Pharmacotherapy of trichotillomania (hair pulling disorder): an updated systematic review. Expert Opin Pharmacother. 2014;15(18):27092719.Google Scholar
Turner, GA, Sutton, S, Sharma, A. Augmentation of venlafaxine with aripiprazole in a case of treatment-resistant excoriation disorder. Innov Clin Neurosci. 2014;11(1–2):2931.Google Scholar
Luca, M, Vecchio, C, Luca, A, Calandra, C. Haloperidol augmentation of fluvoxamine in skin picking disorder: a case report. J Med Case Rep. 2012;6:219.Google Scholar
Phillips, KA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005;162(2):377379.Google Scholar
Phillips, KA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005;162(5):10221023.Google Scholar
Nakaaki, S, Murata, Y, Furukawa, TA. Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder. Psychiatry Clin Neurosci. 2008;62(3):370.CrossRefGoogle ScholarPubMed
Matsunaga, H, Nagata, T, Hayashida, K, Ohya, K, Kiriike, N, Stein, D. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2009;70(6):863868.Google Scholar
Cortese, B, Phan, K. The role of glutamate in anxiety and related disorders. CNS Spectr. 2005;10(10):820830.Google Scholar
Bhattacharyya, S, Chakraborty, K. Glutamatergic dysfunction: newer targets for anti-obsessional drugs. Recent Pat CNS Drug Discov. 2007;2(1):4755.Google Scholar
Stewart, S, Fagerness, J, Platko, J, et al. Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(8):10271033.Google Scholar
Qin, H, Samuels, JF, Wang, Y, et al. Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Mol Psychiatry. 2016;21(2):270276.Google Scholar
Pittenger, C. Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatr Ann. 2015;45(6):308315.Google Scholar
Afshar, H, Roohafza, H, Mohammad-Beigi, H, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32(6):797803.Google Scholar
Paydary, K, Akamaloo, A, Ahmadipour, A, Pishgar, F, Emamzadehfard, S, Akhondzadeh, S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2016;41(2):214219.Google Scholar
Sarris, J, Oliver, G, Camfield, DA, et al. N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs. 2015;29(9):801809.CrossRefGoogle ScholarPubMed
Grant, JE, Odlaug, BL, Kim, SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756763.Google Scholar
Grant, JE, Chamberlain, SR, Redden, SA, Leppink, EW, Odlaug, BL, Kim, SW. N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):490496.CrossRefGoogle ScholarPubMed
Donegan, S, Dixon, P, Hemming, K, Tudur-Smith, C, Marson, A. A systematic review of placebo-controlled trials of topiramate: how useful is a multiple-indications review for evaluating the adverse events of an antiepileptic drug? Epilepsia. 2015;56(12):19101920.Google Scholar
Shank, RP, Gardocki, JF, Streeter, AJ, Maryanoff, BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41 Suppl 1:S3S9.Google Scholar
Berlin, H, Koran, L, Jenike, M, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(5):716721.Google Scholar
Jankovic, J, Jimenez-Shahed, J, Brown, LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81(1):7073.Google Scholar
Lochner, C, Seedat, S, Niehaus, DJ, Stein, DJ. Topiramate in the treatment of trichotillomania: an open-label pilot study. Int Clin Psychopharmacol. 2006;21(5):255259.Google Scholar
Jafferany, M, Osuagwu, FC. Use of topiramate in skin-picking disorder: a pilot study. Prim Care Companion CNS Disord. 2017;19(1): doi: 10.4088/PCC.16m01961.Google Scholar
Jafferany, M, Shireen, F, Ibrahim, A. An open-label trial of topiramate in the treatment of skin picking in pervasive developmental disorder not otherwise specified. Prim Care Companion J Clin Psychiatry. 2010;12(2): pii: PCC.09l00829.Google Scholar
Katoh-Semba, R, Asano, T, Ueda, H, et al. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J. 2002;16(10):13281330.Google Scholar
Pittenger, C, Bloch, MH, Wasylink, S, et al. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry. 2015;76(8):10751084.Google Scholar
Emamzadehfard, S, Kamaloo, A, Paydary, K, et al. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive compulsive disorder: randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2016;70(8):332341.Google Scholar
Grant, PJ, Joseph, LA, Farmer, CA, et al. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology. 2014;39(6):14531459.Google Scholar
Lemmon, ME, Grados, M, Kline, T, Thompson, CB, Ali, SF, Singer, HS. Efficacy of glutamate modulators in tic suppression: a double-blind, randomized control trial of d-serine and riluzole in Tourette syndrome. Pediatr Neurol. 2015;52(6):629634.Google Scholar
Coric, V, Kelmendi, B, Pittenger, C, Wasylink, S, Bloch, MH, Green, J. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania. J Clin Psychiatry. 2007;68(1):170171.Google Scholar
Sasso, DA, Kalanithi, PS, Trueblood, KV, et al. Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors. J Clin Psychopharmacol. 2006;26(6):685687.Google Scholar
Reid, JG, Gitlin, MJ, Altshuler, LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry. 2013;74(7):675684.Google Scholar
Bruno, A, Micò, U, Pandolfo, G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol. 2012;26(11):14561462.CrossRefGoogle ScholarPubMed
Bloom, R, Amber, KT. Identifying the incidence of rash, Stevens–Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. An Bras Dermatol. 2017;92(1):139141.Google Scholar
Plosker, GL, Lyseng-Williamson, KA. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer’s disease. Pharmacoeconomics. 2005;23(2):193206.Google Scholar
Ghaleiha, A, Entezari, N, Modabbernia, A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013;47(2):175180.Google Scholar
Bartoli, F, Riboldi, I, Crocamo, C, Di Brita, C, Clerici, M, Carrà, G. Ketamine as a rapid-acting agent for suicidal ideation: a meta-analysis. Neurosci Biobehav Rev. 2017;77:232236.Google Scholar
Rodriguez, CI, Kegeles, LS, Levinson, A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):24752483.Google Scholar
Rodriguez, CI, Wheaton, M, Zwerling, J, et al. Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial. J Clin Psychiatry. 2016;77(3):408409.Google Scholar
Andrade, C. Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder. J Clin Psychiatry. 2015;76(1):e72e75.CrossRefGoogle ScholarPubMed
Askari, N, Moin, M, Sanati, M, et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2012;26(10):883892.Google Scholar
Shalbafan, M, Mohammadinejad, P, Shariat, SV, et al. Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: a double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2015;48(4–5):136140.Google Scholar
Koran, L, Aboujaoude, E, Bullock, K, Franz, B, Gamel, N, Elliott, M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005;66(3):353359.Google Scholar
Hamon, M, Blier, P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:5463.Google Scholar
Kennedy, SH, Rizvi, SJ. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs. 2009;14(3):439453.Google Scholar
Grados, M, Prazak, M, Saif, A, Halls, A. A review of animal models of obsessive-compulsive disorder: a focus on developmental, immune, endocrine and behavioral models. Expert Opin Drug Discov. 2016;11(1):2743.Google Scholar
Cobb, J. Behaviour therapy in phobic and obsessional disorders. Psychiatr Dev. 1983;1(4):351365.Google Scholar
Manos, RC, Cahill, SP, Wetterneck, CT, Conelea, CA, Ross, AR, Riemann, BC. The impact of experiential avoidance and obsessive beliefs on obsessive-compulsive symptoms in a severe clinical sample. J Anxiety Disord. 2010;24(7):700708.Google Scholar
Katz, D, Rector, NA, Laposa, JM. The interaction of distress tolerance and intolerance of uncertainty in the prediction of symptom reduction across CBT for social anxiety disorder. Cogn Behav Ther. 2017:119.Google Scholar
Costa, DLDC, Barbosa, VS, Requena, G, Shavitt, RG, Pereira, CAB, Diniz, JB. Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder. J Psychopharmacol. 2017:31(10):13121322.Google Scholar
Conceição, CDL, Chagas, AM, Arzeno, FY, et al. Body dysmorphic disorder in patients with obsessive-compulsive disorder: prevalence and clinical correlates. Depress Anxiety. 2012;29(11):966975.Google Scholar
Kelly, MM, Walters, C, Phillips, KA. Social anxiety and its relationship to functional impairment in body dysmorphic disorder. Behav Ther. 2010;41(2):143153.Google Scholar
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: APA; 2013.Google Scholar
Bohne, A, Savage, CR, Deckersbach, T, Keuthen, NJ, Wilhelm, S. Motor inhibition in trichotillomania and obsessive-compulsive disorder. J Psychiatr Res. 2008;42(2):141150.CrossRefGoogle ScholarPubMed
Chamberlain, S, Odlaug, B, Boulougouris, V, Fineberg, N, Grant, J. Trichotillomania: neurobiology and treatment. Neurosci Biobehav Rev. 2009;33(6):831842.Google Scholar
Christenson, GA, Mackenzie, TB. Trichotillomania, body dysmorphic disorder, and obsessive-compulsive disorder. J Clin Psychiatry. 1995;56(5):211212.Google Scholar
Arnold, L, Auchenbach, M, McElroy, S. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs. 2001;15(5):351359.Google Scholar
McGuire, JF, Wu, MS, Piacentini, J, McCracken, JT, Storch, EA. A meta-analysis of d-cycloserine in exposure-based treatment: moderators of treatment efficacy, response, and diagnostic remission. J Clin Psychiatry. 2017;78(2):196206.Google Scholar
Song, C, Stevenson, CW, Guimarães, FS, Lee, JL. Bidirectional effects of cannabidiol on contextual fear memory extinction. Front Pharmacol. 2016;7:493.Google Scholar
Jurkus, R, Day, HL, Guimarães, FS, Lee, JL, Bertoglio, LJ, Stevenson, CW. Cannabidiol regulation of learned fear: implications for treating anxiety-related disorders. Front Pharmacol. 2016;7:454.Google Scholar
Wang, Y, Zhang, X. FAAH inhibition produces antidepressant-like efforts of mice to acute stress via synaptic long-term depression. Behav Brain Res. 2017;324:138145.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×